Immediate Impact
62 standout
Citing Papers
Liquid biopsy in cancer: current status, challenges and future prospects
2024 Standout
Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer
2023 Standout
Works of D. Lau being referenced
A phase Ib safety and tolerability study of a pan class I PI3K inhibitor buparlisib (BKM120) and gefitinib (gef) in EGFR TKI-resistant NSCLC.
2013
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| D. Lau | 39 | 6 | 21 | 14 | 6 | 58 | |
| Andrew Ling | 33 | 7 | 18 | 11 | 6 | 72 | |
| Johan Verschuere | 18 | 11 | 18 | 13 | 6 | 50 | |
| Ji-Young Yun | 24 | 14 | 20 | 14 | 6 | 184 | |
| T Wallis | 56 | 6 | 10 | 6 | 6 | 76 | |
| Anna Maria Villar | 24 | 10 | 22 | 10 | 6 | 62 | |
| Vijay Gunuganti | 37 | 4 | 18 | 28 | 5 | 49 | |
| Anna Pous | 17 | 3 | 13 | 31 | 7 | 53 | |
| Lurdes Planas‐Cerezales | 142 | 15 | 26 | 9 | 12 | 178 | |
| Alexander Guðjónsson | 30 | 16 | 64 | 9 | 6 | 171 | |
| Adrienne E. Borrie | 14 | 8 | 15 | 39 | 6 | 75 |
All Works
Loading papers...